Aims: The efficacy of flash glucose monitoring (flash GM) systems has been demonstrated by improvements in glycaemia; however, during high rates of glucose flux, the performance of continuous glucose monitoring systems was impaired, as detailed in previous studies. This study aimed to determine the performance of the flash GM system during daily-life glycaemic challenges such as carbohydrate-rich meals, bolus insulin-induced glycaemic disturbances and acute physical exercise in individuals with type 1 diabetes.
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| INTRODUCTION
In July 2018 the US Food and Drug Administration (FDA) approved the Freestyle Libre flash glucose monitoring (flash GM) system (Abbott Diabetes Care Inc, USA) to monitor interstitial glucose concentration without obtaining a capillary blood sample from the fingertip for management of type 1 and type 2 diabetes in individuals 18 years of age and older. 1 The beneficial effects of integrating flash GM technology into diabetes management include: reduced time spent in hypoglycaemia, improved glycaemic variability, 2 lower HbA1c levels 3 and increased numbers of readings per day 4 in individuals with type 1 diabetes. 5 Although the flash GM system demonstrated good efficacy in chronic glucose monitoring settings, the accuracy of acute continuous glucose monitoring (CGM) systems was impaired during periods of high rates of change in glucose. 6 From a physiological point of view, a time lag was observed in the interval needed for glucose to diffuse from the bloodstream into the interstitium. 6 In general, use of CGM systems involves a struggle with sensor accuracy during hypoglycaemia and exercise, as shown for both professional (iPro2, Enlite 2, Medtronic, USA) and personal (Minimed 640G, Medtronic;
Freestyle Libre 1, Abbott, USA; Dexcom G4 Platinum, Dexcom, USA) CGM systems. [7] [8] [9] The performance of the flash GM system sensor was found to be accurate, with an overall mean absolute relative difference of approximately 13% under routine environmental conditions. 8 During acute glycaemic challenges such as physical exercise or following carbohydrate-rich meals and high doses of exogenous insulin, the interstitial glucose response may be further delayed. Pleus et al. showed that during periods of rapidly changing blood glucose concentrations of more than −0.2 mmol/L/minute and +0.2 mmol/L/minute the mean absolute relative difference deteriorated from 12.6% and 11.3% to 24.9% and 29.6% for the Dexcom G4
Platinum CGM system (Dexcom, USA). 10 Taking this information into account, there is a need to investigate flash GM performance during exogenously induced glucose excursions to ensure patient safety. Therefore, the aim of this study was to determine the sensor accuracy of the Freestyle Libre flash GM system in individuals with type 1 diabetes during the acute glycaemic challenges of carbohydrate-rich meal ingestion, bolus insulin administration and aerobic physical exercise.
| METHODS
This study is an analysis of a predefined secondary outcome of a clinical trial registered at the German Clinical Trials Register (DRKS.de; DRKS.de; DRKS00013509). This single-centre, randomized, openlabel, four-period 14-hour inpatient cross-over trial was performed in line with Good Clinical Practice and the Declaration of Helsinki. The study protocol was approved by the ethics committee of Health and Care Research Wales, UK (16/WA/0394) and the local health authority. All participants gave written informed consent prior to any trialrelated activities.
| Eligibility criteria
Inclusion criteria are as follows: diagnosis of type 1 diabetes at least 12 months previously; age 18 to 65 years; body mass index of 18.0 to 29.4 kg/m 2 ; use of multiple daily injections (MDI) of insulin for at least 12 months; mass-specific peak oxygen uptake (VO 2peak ) of more than 20 mL/kg/minute; and status of being physically active as assessed by the International Physical Activity Questionnaire Short Form (IPAQ-SF). Main exclusion criteria were: presence of a life-threatening disease; proliferative retinopathy or maculopathy; severe neuropathy; recurrent severe hypoglycaemia (more than one severe hypoglycaemia event during the previous 12 months); hypoglycaemia unawareness as judged by the investigator; hospitalization for diabetic ketoacidosis during the previous 6 months; and any other condition that would interfere with trial participation or evaluation of results as judged by the investigator.
| Screening visit
Anthropometry, body composition, resting cardiovascular markers and HbA1c were measured. Participants performed a peak cardiopulmonary exercise (CPX) test using a semi-recumbent cycle ergometer (Corival Recumbent, Lode, Groningen, The Netherlands). 11 CPX testing comprised a 3-minute resting period without pedalling, followed by a 3-minute warm-up phase with pedalling at 20 W (W).
Thereafter, the exercise workload increased at the end of each minute by 10, 15 or 20 W, dependent on the anticipated functional capacity of the participant, as assessed by an experienced exercise physiologist.
After reaching maximum volitional exhaustion, participants performed an active cool-down for 3 minutes at 20 W, followed by a 3-minute passive cool-down period without pedalling. Maximum volitional exhaustion was defined by one of the following parameters: a lactate concentration greater than10 mmol/L; a respiratory exchange ratio (RER) greater than 1.1; a plateau in oxygen uptake (VO 2 ); or inability to maintain a pedalling cadence of more than 50 rpm (rpm) for 5 seconds. 12 During CPX testing, respiration measurement (METAMAX 3B;
Cortex Biophysik GmbH, Leipzig, Germany), heart rate measurement (S410, Polar Electro, Kmpele, Finland) and electrocardiogram measurement (eMotion Faros 180 , Bittium Biosignals Ltd, Oulu, Finland) were ongoing. Capillary blood glucose and blood lactate from earlobe sampling (20 μL) were taken as follows: at the end of the passive and active warm-up periods; at the end of each incremental step in exercise; and at the end of the active and passive cool-down periods (Biosen C-line, EKF Diagnostic, Barleben, Germany). Blood glucose was measured to minimize the risk of hypoglycaemia and blood lactate was evaluated to prescribe exercise intensity by means of the midpoint of the first (LTP 1 ) and the second lactate turn points (LTP 2 ) (~65% of VO 2peak ). If participants were using insulins other than insulin aspart (Novo Nordisk, A/S, Denmark) and insulin degludec U100 (Novo Nordisk, A/S), they were switched over to these during a maximum period of 28 days prior to the study. This ensured a homogenous study cohort and allowed for a stable therapy, defined as a prebreakfast self-measured blood glucose concentration between 4.0 and 7.0 mmol/L over three consecutive days. If participants were using insulin detemir (Novo Nordisk, A/S) or insulin glargine U100 (Sanofi, France) prior to the trial, the first dose of insulin degludec (Novo Nordisk, A/S) was 80% of their pre-study total basal insulin dose. Participants using insulin glargine U300 (Sanofi) were switched over to insulin degludec (Novo Nordisk, A/S) with a 1:1 dose at the beginning.
If participants were already using insulin degludec, they were also expected to achieve the titration target within 28 days. If adjustment of the dose of insulin degludec (Novo Nordisk, A/S) was required, this was undertaken every 3 days. Participants received an unblinded flash GM system (FreeStyle Libre, Abbott Diabetes Care Inc., USA) and spare sensors. Participants were trained in use of the system and the first flash GM sensor was inserted under instruction by the research team. Participants were told to change the sensor at least 48 hours before each trial visit to avoid sensor expiration during the research period and to avoid assessment of flash GM performance during the initial warm-up period.
| Trial visits
Trial visits were separated by at least five working days. Participants were randomized to the following alternating pre-and post-exercise bolus insulin doses:
• 50%-reduced pre-exercise and 50%-reduced post-exercise dose of insulin aspart with a carbohydrate-rich meal.
• Regular pre-exercise and regular post-exercise dose of insulin aspart.
• 50%-reduced pre-exercise and regular post-exercise dose of insulin aspart.
• Regular pre-exercise and 50%-reduced post-exercise dose of insulin Aspart.
Throughout each of the four 14-hour inpatient phases, participants received three carbohydrate-rich meals and venous blood glucose concentration was compared to interstitial glucose concentration ( Figure 1 ). During exercise, only capillary blood was obtained from the earlobe, with resultant glucose concentrations compared to interstitial glucose concentration; these values were analysed separately because of collection from a different compartment. In this study, only scanned data were used for assessment of the flash GM system; at the time a blood sample was taken, a scan was performed using the flash GM system and these data were assessed for accuracy. 13 
| Statistical analyses
Data were analysed for normal distribution using Shapiro-Wilk testing to assess whether median or mean absolute relative difference must be shown. Flash GM sensor performance was analysed using median absolute relative difference (MARD) (IQR), the Bland-Altman method and the Clarke error grid, as well as according to guidelines for integrated CGM approvals (Class II-510(K)). 16 The Clarke error grid is divided into zones to evaluate the risk caused by inaccuracy of measurement. Values were stratified for glycaemic ranges, defined as hypoglycaemia level 1 (≤3.9 mmol/L), euglycaemia (4.0-9.9 mmol/L) and hyperglycaemia (≥10 mmol/L). 17 Furthermore, data were stratified for day-time of agreement from −0.64 mmol/L to 6.08 mmol/L (Figure 2) . Data from assessment of the performance of the flash GM system according to guidelines for integrated CGM approvals (Class II-510 (K)) are shown in Table 2 .
The Clarke error grid showed that, overall, 56% of values were located in zone A, 35% in zone B, 9% in zone D, and no values were located in zones C and E. During exercise, 26% of values were located in zone A, 52% in zone B, 22% in zone D, and no values were located in zones C and E (Figure 3 ). The 
| DISCUSSION
This is the first study to assess the performance of the flash GM system with different rates of change in glucose in a clinical research facility setting, comprising acute daily-life challenges such as carbohydrate-rich meals, bolus insulin administration and physical exercise. MARDs' for the night-time period were similar to findings of a recent study in which a mean absolute relative difference of 13% ± 11% was found for the flash GM system. 8 During acute exercise, the results of our study using the flash GM system deviated con- GM interstitial glucose values were far off the expected relative range (Class II-510(K)). When evaluating the clinical accuracy of the flash GM system using the Clark error grid, only 56% of values overall and 26% of values during exercise were located in zone A. Additionally, F I G U R E 3 Clinical assessment of the flash GM system and its relationship to reference blood glucose levels using the Clarke error grid. A, Overall 56% of values were located in zone A, 35% in zone B, 9% in zone D and no values were in zones C and E. B, During exercise, 26% of values were located in zone A, 52% in zone B, 22% in zone D and no values were in zones C and E the fact that 9% of values overall and 22% of values during exercise were located in zone D clearly indicates that the flash GM system has major weaknesses, and decisions based on the displayed values are questionable.
Our study is limited by the rather small number of participants; however, this limitation was compensated for by four visits in a crossover fashion. Additionally, during exercise testing, we analysed the accuracy of the flash GM system in relation to capillary blood glucose concentration, which may have resulted in less accurate blood glucose values.
In conclusion, the flash GM system displayed an impaired performance during acute exercise and during periods of hypoglycaemia where it is inconvenient and difficult to perform capillary blood glucose measurements in individuals with type 1 diabetes. Our results also demonstrated that the performance of the flash GM system is linked to the rate of change in blood glucose. Adjuvant blood glucose measurements are encouraged during physical exercise and/or in the context of low blood glucose concentrations to avoid episodes of severe hypoglycaemia as the result of systematic overestimation of interstitial glucose levels as compared to blood glucose levels.
